HealthEconomics.Com Founder and CEO Patti Peeples, PhD, recently discussed some of the changes in health economics and outcomes research (HEOR) and real-world evidence (RWE), and how those changes could impact the publication planning industry.
Peeples, who is set to deliver the keynote address at RISE’s 18th Annual International Publication Planning Meeting Feb. 20-21 in San Diego, tells RISE the evolving landscape of HEOR and RWE have opened opportunities for expert communicators who can effectively explain a drug’s value to payers, patients and providers.
“I’m most excited about the development of the Food and Drug Administration’s use of real-world data and new drug approval,” Peeples said, adding that real-world evidence can play a key role in boosting understanding, improving outcomes and cutting costs.
With the rise of innovative technologies that bear enormous potential, including predictive analytics and artificial intelligence, Peeples also foresees a growing need for communicators well-versed in those particular data communication needs.
“I hope we’ll begin as a group to better understand where we are right now in value communication by each stakeholder: one that develops the data, one that analyzes the data, the ones that write up the results, and the ones that receive the information,” she tells RISE.
Peeples is slated to deliver her keynote address, “The Value of a Drug — What it Means, Why it Matters, and How to Communicate it,” 9 a.m. Feb. 20 at RISE’s upcoming event.
To read more of Peeples’ conversation with RISE, click here.
For additional information and registration details about RISE’s 18th Annual International Publication Planning Meeting, click here.